"The voice for cancer physicians and their patients in Massachusetts."

FDA approved venetoclax (Venclexta) for CCL or SLL with or without 17p deletion

29 Jun 2018 9:43 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration granted regular approval to venetoclax (Venclexta; AbbVie and Genentech) for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy. Read full press release.

Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software